“48% of trial sites miss enrollment targets and study timelines, nearly doubling the original duration in order to meet enrollment levels.”
Source: Tufts Center for the Study of Drug Development

“Trial delays translate into increased costs and lost revenue. In fact, 30% of all Phase III study terminations are due to enrollment difficulties, making recruitment the single biggest reason for trial failure.”
Source: Parexel Biopharmaceutical R&D Statistical Sourcebook, 2012/2013.

Conducting objective third-party market research with clinical trial sites has the potential of significantly impacting the rate of screening and enrollment, resulting in earlier trial completion.